ArticleInternational wound journal2016
Refractory sickle cell leg ulcer: is heparan sulphate a new hope?
Article in International wound journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Brief topical sodium nitrite and its impact on the quality of life in patients with sickle leg ulcers.Medicine · 2018Trial
- A Prospective Cohort Study of Hard-to-Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add-on to Optimal Local Care.International wound journal · 2026Article
- ReGeneraTing Agents (rgtaClinical case reports · 2021Article
- Leg Ulcers in Sickle-Cell Disease: Treatment Update.Advances in wound care · 2020Review
- Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTAVeterinary sciences · 2019Article
- ReGeneraTing Agents (RGTAClinical case reports · 2019Article
- ReGeneraTing Agents (RGTAClinical case reports · 2018Article
- RGTAGlycoconjugate journal · 2017Review
- A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease.International wound journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with sickle cell disease are known to have recurrent lower extremity ulcers that have a high pain score and are resistant to conventional means of wound therapy. This study reports the successful use of synthetic heparan sulphate (Cacipliq20(®) , OTR3, Paris, France) in the treatment of a sickle cell ulcer that had failed to respond to several other means of treatment. Therapeutic success was assessed by complete wound coverage and vast improvement in pain score. This is the first study to report use of heparan sulphate in sickle cell ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.